Sophocarpine alleviates non-alcoholic steatohepatitis in rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 4, 2011, Pages 765-774

  Song, Chun Yan ^a   Zeng, Xin ^a   Chen, Si Wen ^b   Hu, Ping Fang ^a   Zheng, Zhi Wu ^c   Ning, Bei Fang ^a   Shi, Jian ^a   Xie, Wei Fen ^a   Chen, Yue Xiang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c No 411 Hospital of PLA   (China)

Author keywords

Adipocytokine; Non alcoholic steatohepatitis; Pro inflammatory cytokine; Sophocarpine

Indexed keywords

ALKALOID; ALPHA SMOOTH MUSCLE ACTIN; INTERLEUKIN 6; LEPTIN; MESSENGER RNA; PROCOLLAGEN; PROCOLLAGEN TYPE 1; SOPHOCARPINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEPATITIS; HISTOPATHOLOGY; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THERAPY EFFECT;

EID: 79952848680     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06561.x     Document Type: Article

References (48)

1. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-7.
2. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int. J. Biochem. Cell Biol. 2009; 41: 969-76.
3. Kohli R, Boyd T, Lake K etal. Rapid progression of NASH in childhood. J. Pediatr. Gastroenterol. Nutr. 2010; 50: 453-6.
4. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009; 51: 371-9.
5. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
6. Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann. Clin. Lab. Sci. 2004; 34: 57-62.
7. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-19.
8. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 2001; 96: 2711-17.
9. Abdelmalek MF, Sanderson SO, Angulo P etal. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50: 1818-26.
10. Chen SW, Chen YX, Shi J, Lin Y, Xie WF. The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Dig. Dis. Sci. 2006; 51: 2225-34.
11. Ratziu V, Zelber-Sagi S. Pharmacologic therapy of non-alcoholic steatohepatitis. Clin. Liver Dis. 2009; 13: 667-88.
12. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J. Gastroenterol. Hepatol. 2007; 22: 778-87.
13. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 290: G852-8.
14. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-80.
15. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
16. Zhang Y, Wang S, Li Y, Xiao Z, Hu Z, Zhang J. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. Int. Immunopharmacol. 2008; 8: 1767-72.
17. Han Y, Zhou Y, Liu Q. Antiendotoxic effects of Sophora alopecuroides L. Zhong Yao Cai 2006; 29: 1066-9.
18. Qavi HB, Wyde PR, Khan MA. In vitro inhibition of HHV-6 replication by sophocarpines. Phytother. Res. 2002; 16: 154-6.
19. Ding PL, Liao ZX, Huang H, Zhou P, Chen DF. (+)-12alpha-hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens. Bioorg. Med. Chem. Lett. 2006; 16: 1231-5.
20. Guo B, Li C, Deng Z etal. A new method for measurement of (-)-sophocarpine, a candidate therapeutic for viral myocarditis, in plasma: application to a toxicokinetic study in beagle dogs. Rapid Commun. Mass Spectrom. 2005; 19: 2840-8.
21. Chen SX, Xu J, Wang PQ etal. Study of sophocarpine in human pharmacokinetic. Shanghai Second Med. Univ. J. 2005; 25: 1164-66.
22. Mendler MH, Kanel G, Govindarajan S. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int. 2005; 25: 294-304.
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
24. Park KS, Lee YS, Park HW etal. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J. Intern. Med. 2004; 19: 19-26.
25. Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology 2010; 51: 690-8.
26. Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ. Effects of traditional Chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation 2008; 31: 121-32.
27. Gao Y, Li G, Li C etal. Anti-nociceptive and anti-inflammatory activity of sophocarpine. J. Ethnopharmacol. 2009; 125: 324-9.
28. Feldstein AE, Werneburg NW, Canbay A etal. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-94.
29. Tripathy D, Mohanty P, Dhindsa S etal. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-7.
30. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 2006; 44: 197-208.
31. Arkan MC, Hevener AL, Greten FR etal. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005; 11: 191-8.
32. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
33. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 2005; 21: 702-7.
34. Tomita K, Tamiya G, Ando S etal. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2007; 55: 415-24.
35. Hsieh PS, Jin JS, Chiang CF etal. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity 2009; 20: 1150-7.
36. Pessayre D, Bearson A, Fromenty B etal. Mitochondria in steatohepatitis. Semin. Liver Dis. 2001; 21: 57-69.
37. Wynn TA. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008; 214: 199-210.
38. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 2006; 26: 8-22.
39. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J. Gastroenterol. 2008; 43: 811-22.
40. Krawczyk K, Szczesniak P, Kumor A etal. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J. Physiol. Pharmacol. 2009; 60: 71-5.
41. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm. 2009; 2009: 831670.
42. Hui JM, Hodge A, Farrell GC etal. Beyond insulin resistance in NASH: TNF-alpha or adiponectin. Hepatology 2004; 40: 46-54.
43. Kaser S, Moschen A, Cayon A etal. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-21.
44. Ikejima K, Honda H, Yoshikawa M etal. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001; 34: 288-97.
45. Marra F. Leptin and liver fibrosis: a matter of fat. Gastroenterology 2002; 122: 1529-32.
46. Kamada Y, Matsumoto H, Tamura S etal. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 2007; 47: 556-64.
47. Xu A, Wang Y, Keshaw H etal. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003; 112: 91-100.
48. Masaki T, Chiba S, Tatsukawa H etal. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-84.